Publication Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy Nicola Specchio, Nicola Pietrafusa, Marina Trivisano
Press Release BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
Press Release BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
Press Release BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
